The iShares IXJ ETF provides investors with a targeted exposure to over 100 global healthcare companies. This includes companies in the pharmaceutical, biotechnology, and medical device space.
A Best ETFs No Rating rating is a fund rating our analysts apply to funds, LICs, mFunds, or ETFs that represents a ‘pending’ or ‘not yet researched’ status for the fund/ETF.
Please note, our rating methodology, research cycle, and process are currently being updated and will soon include full analyst ETF notes, reports, interviews, research, and ratings on select Australian ETFs and funds.
Be sure to subscribe to our mailing list or take our free ETF course while you wait for the updated features. If you’re a fund manager looking to get your fund independently rated by our team, please get in contact.
IXJ invests in a portfolio of global healthcare companies, including leading brands like Johnson & Johnson, CSL and Glaxosmithkline. Trying to replicate this exposure to healthcare stocks yourself would be time-consuming and expensive, so IXJ could be a solution for investors looking for a targeted exposure to this sector.
IXJ could be used by investors to gain a tactical exposure to the global healthcare sector, and has a strong geographical exposure to the US market. This ETF aims to track the S&P Global 1200 Healthcare Sector Index, before fees and expenses.
The Best ETFs technical analysis chart pack shows the 12-month share price movements, Stochastic bands and traded volume (for both up and down days). This chart uses end-of-day data, so it’s for illustrative purposes only.
*The warnings on this page are applied by our ETF research team. Please know that these warnings are based on quantitative metrics and our internal methodology. These risks are not exhaustive and therefore they should not be relied upon. Always read the PDS of the function and speak to your financial adviser before acting on this information.
Right now, there are 200+ ETFs on the ASX. Then there are index funds. Hundreds of managed funds. LICs. REITs. And everything in between. Wouldn’t it be nice to make ONE investment and build the strong Core of your portfolio — with just one click?
Rask’s lead ETF research analyst and investing team have identified our #1 ETF for 2021 and beyond. Our analyst team has put together a full research report and a step-by-step investment guide to buying this ETF.